Jordan Harborth
Nurse Practitioner · Austin, TXNPI 1174908677
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 50.0% of the total. Reporting peaked in 2021 at $11,587 and has fallen 96.5% since, to $408 in 2025. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $66.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$14K
- MDD US Operations, LLC$5K
- Amneal Pharmaceuticals LLC$2K
- Acadia Pharmaceuticals Inc$2K
- Abbott$1K
- Teva Pharmaceuticals USA, Inc.$817
- plus $4K from 26 others
Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$210
What the payments were for
- Consulting fees$3,08311%
- Speaking & faculty fees$15,36357%
- Travel & lodging$250%
- Food & beverage$7,33127%
- Education$1,3365%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 44 | $13,558 |
| MDD US Operations, LLC | 23 | $4,521 |
| Amneal Pharmaceuticals LLC | 20 | $1,736 |
| Acadia Pharmaceuticals Inc | 50 | $1,733 |
| Abbott | 42 | $1,094 |
| Teva Pharmaceuticals USA, Inc. | 42 | $817 |
| Ipsen Biopharmaceuticals, Inc | 22 | $494 |
| Acorda Therapeutics, Inc | 24 | $471 |
| Kyowa Kirin, Inc. | 19 | $395 |
| Medtronic | 25 | $379 |
| AbbVie | 9 | $221 |
| Merz Pharmaceuticals, LLC | 6 | $207 |
| Adamas Pharmaceuticals, Inc. | 13 | $193 |
| GE HealthCare | 9 | $173 |
| Sunovion Pharmaceuticals Inc. | 14 | $144 |
| Avion Pharmaceuticals | 6 | $126 |
| Biogen | 5 | $107 |
| Boston Scientific | 2 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| Insightec,inc | 4 | $83 |
| GRT US Holding, Inc. | 3 | $77 |
| Eisai Inc. | 3 | $68 |
| UCB, Inc. | 3 | $67 |
| Piramal Critical Care | 4 | $63 |
| Lundbeck LLC | 2 | $54 |
| Averitas Pharma Inc. | 2 | $36 |
| Cala Health, Inc. | 1 | $33 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Octapharma USA, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Metacel Pharmaceuticals LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,137 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 44 | $339,839 |
| GocovriAmantadine Hcl | 27 | $103,242 |
| RytaryCarbidopa/Levodopa | 68 | $69,611 |
| Droxidopa | 11 | $42,989 |
| NourianzIstradefylline | 12 | $28,929 |
| OngentysOpicapone | 17 | $25,671 |
| Rasagiline Mesylate | 82 | $17,847 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 152 | $12,794 |
| Rivastigmine | 46 | $9,856 |
| Entacapone | 37 | $7,730 |
| Selegiline Hcl | 82 | $7,696 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 155 | $6,566 |
| Ropinirole ErRopinirole Hcl | 21 | $6,300 |
| Primidone | 109 | $3,155 |
| AmantadineAmantadine Hcl | 46 | $2,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $1,733 | $339,83944 claims |
| MDD US Operations, LLCGocovri | $4,521 | $103,24227 claims |
| Amneal Pharmaceuticals LLCRytary | $1,736 | $69,61168 claims |
| Kyowa Kirin, Inc.Nourianz | $395 | $28,92912 claims |
| Neurocrine Biosciences, Inc.Ongentys | $13,558 | $25,67117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Austin
- Cecilia DavisAustin$262K
- Patricia MedinaAustin$64K
- Natasha GibbsAustin$20K
- Kaycee FrederickAustin$17K
- Melissa SaulsAustin$15K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Corrie BerkSan Antonio$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.